Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia

Internal Medicine

Volumn 52, Issue 19, 2013, Pages 2193-2201

  Oshima, Yasuo ^a,b   Yuji, Koichiro ^a   Tanimoto, Tetsuya ^b,c   Hinomura, Yasushi ^d   Tojo, Arinobu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER INSTITUTE   (Japan)

^c Navitas Clinic   (Japan)

^d Japan Pharmaceutical Information Center (JAPIC)   (Japan)

Author keywords

FDA adverse event reporting system (FAERS); Immune thrombocytopenia (ITP); Myeloproliferative leukemia virus proto oncogene product (MPL); Spontaneous report; Thrombopoietin receptor agonist

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DASATINIB; ELTROMBOPAG; ETHOTOIN; FOSPHENYTOIN SODIUM; GOLIMUMAB; IMATINIB; IMMUNOGLOBULIN; LAPATINIB; METHOTREXATE; METHYLPREDNISOLONE; MITOMYCIN; NELARABINE; NILOTINIB; PHENYTOIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; RETINOIC ACID; RITUXIMAB; ROMIPLOSTIM; TEMOZOLOMIDE; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; THROMBOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; YOUNG ADULT;

EID: 84884927097     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.0324     Document Type: Article

References (41)

1. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 89: 5640-5644, 1992.
2. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63: 1137-1147, 1990.
3. Wendling F, Vigon I, Souyri M, Tambourin P. Myeloid progenitor cells transformed by the myeloproliferative leukemia virus proliferate and differentiate in vitro without the addition of growth factors. Leukemia 3: 475-480, 1989.
4. Wendling F, Penciolelli JF, Charon M, Tambourin P. Factor-independent erythropoietic progenitor cells in leukemia induced by the myeloproliferative leukemia virus. Blood 73: 1161-1167, 1989.
5. Liebman HA, Pullarkat V. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Hematology Am Soc Hematol Educ Program 2011: 384-390, 2011.
6. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 28: 437-444, 2010.
7. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 367: 11-19, 2012.
8. Oshima Y, Yuji K, Tojo A. Eltrombopag in refractory aplastic anemia. N Engl J Med 367: 1162-1163, 2012.
9. Hauben M, Reich L, DeMicco J, Kim K. 'Extreme duplication' in the US FDA Adverse Events Reporting System database. Drug Saf 30: 551-554, 2007.
10. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 33: 303-314, 2010.
11. Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol 23: 694-704, 2013.
12. Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med 50: 845-853, 2011.
13. Oshima Y, Tojo A. Attractive tools for systematic case accumulation. Int J Hematol 94: 413-414, 2011.
14. Oshima Y, Tojo A. Pulmonary alveolar hemorrhage possibly associated with lenalidomide use. Int J Hematol 94: 296-297, 2011.
15. Oshima Y. Characteristics of 1,544 Drug-induced Hypersensitivity Syndrome Cases Reported to Food and Drug Administration. DMC DERMATOLOGY 2: WMC001980, 2011.
16. Levine SP. IDIOPATHIC AUTOIMMUNE THROMBOCY-TOPENIC PURPURA. In: Wintrobe's Clinical Hematology. 53rd ed. Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, Eds. Lippincott Williams & Wilkins, Philadelphia, 2004: 1534-1544.
17. American Cancer Society. Cancer facts & figures 2008, 2009.
18. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haema-tol 135: 642-650, 2006.
19. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 281: 824-829, 1999.
20. Miremont G, Haramburu F, Begaud B, Pere JC, Dangoumau J. Adverse drug reactions: physicians' opinions versus a causality assessment method. Eur J Clin Pharmacol 46: 285-289, 1994.
21. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 24: 233-237, 2001.
22. Stang PE, Fox JL. Adverse drug events and the Freedom of Information Act: an apple in Eden. Ann Pharmacother 26: 238-243, 1992.
23. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepide-miol Drug Saf 13: 519-523, 2004.
24. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26: 404-413, 1934.
25. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombo-cythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood 92: 1091-1096, 1998.
26. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 18: 49-52, 1998.
27. Ghilardi N, Skoda RC. A single-base deletion in the throm-bopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood 94: 1480-1482, 1999.
28. Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol 107: 310-316, 1999.
29. Oshima Y, Komatsu N, Ozawa K, Fujimura A. CML Developed in a Japanese Family Transmitting a Novel Point Mutation in the Thrombopoietin Gene (TPO). ASH Annual Meeting Abstracts 104: 4220, 2004.
30. Liu K, Kralovics R, Rudzki Z, et al. A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythe-mia in a Polish family. Haematologica 93: 706-714, 2008.
31. Graziano C, Carone S, Panza E, et al. Association of hereditary thrombocythemia and distal limb defects with a thrombopoietin gene mutation. Blood 114: 1655-1657, 2009.
32. Posthuma HL, Skoda RC, Jacob FA, van der Maas AP, Valk PJ, Posthuma EF. Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood 116: 3375-3376, 2010.
33. Zhang B, Ng D, Jones C, et al. A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood 118: 6988-6990, 2011.
34. Stockklausner C, Echner N, Klotter AC, Hegenbart U, Dreger P, Kulozik AE. Hereditary thrombocythemia caused by a throm-bopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects. Ann Hematol 91: 1129-1133, 2012.
35. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombo-cythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for throm-bopoietin. Blood 103: 4198-4200, 2004.
36. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108: 3472-3476, 2006.
37. Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombo-cythemia. J Clin Oncol 25: 1048-1053, 2007.
38. Teofili L, Giona F, Martini M, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 110: 3384-3386, 2007.
39. El-Harith HA, Roesl C, Ballmaier M, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol 144: 185-194, 2009.
40. Liu K, Martini M, Rocca B, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica 94: 1368-1374, 2009.
41. Teofili L, Giona F, Torti L, et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Hae-matologica 95: 65-70, 2010.